Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.

Cite

CITATION STYLE

APA

Amaador, K., Thieblemont, C., Trotman, J., & Minnema, M. C. (2023, November 1). Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström’s macroglobulinemia. Hematological Oncology. John Wiley and Sons Ltd. https://doi.org/10.1002/hon.3210

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free